slides · global inventory
Consultants Gambit
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 39,432
Current window 32,011-32,040
Pages 1,315
Rows per page 30
Arc
32,011-32,040 of 39,432
47
Branded Argenx presentation slide.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
48
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
49
Includes names of presenters and company logo.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
50
The diagram shows the classical, lectin, and alternative pathways converging at C3 convertase, with C2 highlighted as a target.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
51
The slide uses a process flow diagram to illustrate the complement system and justifies targeting C2 over other components.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
52
The slide uses a process flow diagram to explain the mechanism of action for a potential therapeutic intervention.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
53
The slide uses a biological pathway diagram to justify a therapeutic target.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
54
The slide uses a process flow diagram to justify targeting C2. It contrasts this with other potential targets (labeled 1 and 2) and highlights the benefits of C2 inhibition.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
55
The slide uses a circular process diagram to explain the biological mechanism of the drug.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
56
The slide uses a timeline-like structure to show dose escalation cohorts for IV and SC administration.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
57
The slide presents clinical trial safety data for ARGX-117, highlighting that most adverse events are low grade and unrelated to the drug.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
58
SAD = Single Ascending Dose. PD = Pharmacodynamic.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
59
The slide shows two line charts comparing different dosing regimens over time.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
60
The chart compares three dosing regimens (60mg/kg LD + 10mg/kg Q2W, 40mg/kg Q4W, 60mg/kg Q8W) against a 99% reduction threshold.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
61
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
62
The slide highlights the clinical burden and market opportunity for new therapies.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
63
The slide uses a numbered list format to explain a biological mechanism and clinical correlation.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
64
The slide uses immunofluorescence microscopy to demonstrate the efficacy of ARGX-117 in preventing complement-mediated damage.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
65
The slide uses a visual gradient to represent dose-dependency in a biological assay.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
66
The slide uses a before-after comparison to demonstrate the efficacy of ARGX-117 in preserving neurofilaments.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
67
The slide uses a process flow diagram to illustrate the clinical trial stages.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
68
The diagram uses a Venn-like structure nested within a larger circle to show the relationship between biological pathways, therapeutic franchises, and specific disease indications.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
69
The slide features a list of 11 individuals with their professional titles and affiliations.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
01
Aston Martin | Results Presentation Deck | 25 slidesAston Martin | Results Presentation Deck | 25 slides · Aston Martin Lagonda
Conference presentation Investor relations Beat · Situation & Context1 hit
02
The slide features a prominent image of an Aston Martin Valhalla concept car.Aston Martin | Results Presentation Deck | 25 slides · Aston Martin Lagonda
Conference presentation Investor relations Beat · Situation & Context1 hit
03
Includes a footnote regarding board diversity.Aston Martin | Results Presentation Deck | 25 slides · Aston Martin Lagonda
Conference presentation Investor relations Beat · Situation & Context1 hit
04
The slide features a high-quality photograph of an Aston Martin safety car in a garage setting, with the name and title overlaid.Aston Martin | Results Presentation Deck | 25 slides · Aston Martin Lagonda
Conference presentation Investor relations Beat · Situation & Context1 hit
05
The slide uses a before-after comparison style for financial performance metrics.Aston Martin | Results Presentation Deck | 25 slides · Aston Martin Lagonda
Conference presentation Investor relations Beat · Situation & Context1 hit
06
Includes YoY change percentages and regional volume comparisons.Aston Martin | Results Presentation Deck | 25 slides · Aston Martin Lagonda
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
07
The chart illustrates the revenue growth drivers for Aston Martin Lagonda.Aston Martin | Results Presentation Deck | 25 slides · Aston Martin Lagonda
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit